Repros Therapeutics Inc. (RPRX)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Pablo G. Legorreta
Employees:
70
110 EAST 59TH STREET, NEW YORK, NY 10022
(212) 883-0200

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Royalty Pharma plc was founded in 1996 and is based in New York, New York. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates.

Data derived from most recent annual or quarterly report
Market Cap 260.049 Million Shares Outstanding388.132 Million Avg 30-day Volume 460.853 Thousand
P/E Ratio48.1401 Dividend Yield1.8417 EPS1.26
Price to Revenue10.8574 Debt to Equity0.6827 EBITDA1.088 Billion
Price to Book Value3.9659 Operating Margin41.97 Enterprise Value33.483 Billion
Current Ratio2.07 EPS Growth-0.418 Quick Ratio1.959
1 Yr BETA 0.4538 52-week High/Low 0.0 / Profit Margin39.773
Operating Cash Flow Growth-1.3972 Altman Z-Score2.6263 Free Cash Flow to Firm 411.565 Million

Are you looking for this stock instead?

View SEC Filings from RPRX instead.

View recent insider trading info

Repros Therapeutics Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding RPRX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RPRX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 3/A: filed on 2020-06-17 by COYNE TERRANCE P.
  • 4: filed on 2018-01-31 by WYLLIE MICHAEL
  • 4: filed on 2018-01-31 by FOURTEAU PATRICK
  • 4: filed on 2018-01-31 by RAMASASTRY SAIRA
  • 4: filed on 2018-01-31 by MASTERSON NOLA E
  • 4: filed on 2018-01-31 by CAIN DANIEL F
  • 4: filed on 2018-01-31 by ANDERSON KATHERINE
  • 4: filed on 2017-09-18 by WYLLIE MICHAEL
  • 4: filed on 2017-09-18 by RAMASASTRY SAIRA
  • 4: filed on 2017-09-18 by MASTERSON NOLA E

    • Events (8k)

  • 8-K: filed on 2018-01-31:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-01-26:
    Item 8.01: Other Events
  • 8-K: filed on 2017-12-15:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2017-12-15:
    Item 8.01: Other Events
  • 8-K: filed on 2017-12-12:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-11-13:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-11-13:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2017-10-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-09-15:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2017-09-11:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    ENGELBERT CATHERINE M.

    • Director
    		 0 2020-06-16 0

    RIGGS RORY B

    • Director
    		 0 2020-06-15 0

    ADAGE CAPITAL PARTNERS GP, L.L.C.

    ADAGE CAPITAL PARTNERS, L.P.

    ADAGE CAPITAL ADVISORS, L.L.C.

    ATCHINSON ROBERT

    GROSS PHILLIP

    • 10% Owner
    		 0 2020-06-15 0

    FORD WILLIAM E

    • Director
    		 0 2020-06-15 0

    DESOUZA ERROL B

    • Director
    		 0 2020-06-15 0

    NORDEN GREGORY

    • Director
    		 0 2020-06-15 0

    LEGORRETA PABLO G. CEO, CHAIRMAN OF THE BOARD

    • Officer
    • Director
    		 0 2020-06-15 0

    BASSLER BONNIE L

    • Director
    		 0 2020-06-15 0

    HITE CHRISTOPHER EVP & VICE CHAIRMAN

    • Officer
    		 0 2020-06-15 0

    REDDOCH JAMES F. EVP, RESEARCH & INVESTMENTS

    • Officer
    		 0 2020-06-15 0

    COYNE TERRANCE P. EVP & CFO

    • Officer
    		 0 2020-06-15 0

    GIULIANI MARIO GERMANO

    SKYELINE MANAGEMENT LTD

    AVARA MANAGEMENT LTD

    NOGRA GROUP SICAF SIF MGG STRATEGIC

    NOGRA GROUP SICAF SIF GG STRATEGIC

    NOGRA GROUP SICAF - SIF S.A.

    SEVERGNINI ACHILLE G.

    • Director
    • 10% Owner
    		 0 2020-06-15 0

    LLOYD GEORGE W. EVP, INVESTMENTS & GC

    • Officer
    		 0 2020-06-15 0

    FOURTEAU PATRICK

    • Director
    		 No longer subject to file 2018-01-29 0

    CAIN DANIEL F

    • Director
    		 No longer subject to file 2018-01-29 0

    MASTERSON NOLA E

    • Director
    		 No longer subject to file 2018-01-29 0

    ANDERSON KATHERINE CHIEF FINANCIAL OFFICER

    • Officer
    		 No longer subject to file 2018-01-29 0

    WYLLIE MICHAEL

    • Director
    		 No longer subject to file 2018-01-29 0

    RAMASASTRY SAIRA

    • Director
    		 No longer subject to file 2018-01-29 0

    DILLAHA LARRY INTERIM PRESIDENT AND CEO

    • Officer
    		 0 2017-02-01 0

    THOMPSON JAYE SEE REMARKS

    • Officer
    		 0 2016-07-05 0

    WERNICKE J. F. CHIEF MEDICAL OFFICER

    • Officer
    		 0 2016-07-05 0

    SUESSERMAN MICHAEL

    • Director
    		 0 2015-05-28 0

    PODOLSKI JOSEPH PRESIDENT AND CEO

    • Officer
    • Director
    		 0 2014-03-26 0

    WIEHLE RONALD VP, RESEARCH AND DEVELOPMENT

    • Officer
    		 0 2014-03-26 0

    PERCEPTIVE ADVISORS LLC

    EDELMAN JOSEPH

    PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

    • 10% Owner
    		 No longer subject to file 2013-03-15 0

    FOURCROY JEAN L MD PHD MPH

    • Director
    		 0 2012-06-13 0

    OLIVEIRA STEVEN MICHAEL

    • 10% Owner
    		 1,315,672 2011-04-19 0

    PERCEPTIVE ADVISORS LLC

    PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

    • 10% Owner
    		 1,144,365 2011-02-24 0

    EFFICACY CAPITAL, LTD.

    EFFICACY BIOTECH FUND L.P.

    LAPPE MARK

    EFFICACY BIOTECH FUND LTD

    EFFICACY BIOTECH MASTER FUND LTD.

    • 10% Owner
    		 No longer subject to file 2009-12-17 0

    REED JOHN C

    • Director
    		 0 2009-05-20 0

    LAPPE MARK

    • Director
    • 10% Owner
    		 0 2009-05-20 0

    HOWELL STEPHEN B.

    • Director
    		 0 2009-05-20 0

    VAN AS ANDRE MD, PHD CHIEF MEDICAL OFFICER

    • Officer
    		 10,410 2009-04-14 0

    PLOTH LOUIS JR VP & CHIEF FINANCIAL OFFICER

    • Officer
    • Director
    		 0 2009-02-18 0

    LAMMERS PAUL PRESIDENT

    • Officer
    		 0 2009-02-18 0

    POORVIN DAVID

    • Director
    		 0 2008-05-14 0

    HARDER JEFFREY R

    • Director
    		 0 2008-05-14 0

    EFFICACY CAPITAL, LTD.

    LAPPE MARK

    KAYYEM JON FAIZ

    EFFICACY BIOTECH FUND L.P.

    EFFICACY BIOTECH FUND LTD

    EFFICACY BIOTECH MASTER FUND LTD.

    • 10% Owner
    		 2,277,956 2008-03-14 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments